| Mr Frank Charles Damico, MD | |
|
815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109-4839 | |
| (717) 724-0720 | |
| (717) 724-0730 |
| Full Name | Mr Frank Charles Damico |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 36 Years |
| Location | 815 Sir Thomas Ct Ste 200, Harrisburg, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508866534 | NPI | - | NPPES |
| 01018901 | Other | PA | CAPITAL BLUE CROSS |
| 4603161 | Other | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD042343L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Geisinger St. Luke's Hospital | Orwigsburg, PA | Hospital |
| Pinnacle Health Hospitals | Harrisburg, PA | Hospital |
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| St Luke's Miners Memorial Hospital | Coaldale, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gslpg, Inc | 7810226875 | 227 |
News Archive
Abortion opponents have found a new way to restrict access to abortion - by using the authority states have over the new health insurance exchanges, which will be up and running in a year. At least 21 states have legislation in place or in the works that will stop health insurance companies from paying for abortions for women.
On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA's current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.
Baxter International Inc. and Takeda Pharmaceutical Company Limited today announced that the parties have completed a Development, License and Technology Transfer Agreement. Under the terms of the agreement, Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market.
Forward Pharma A/S, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares.
Cambridge Enterprise has exclusively licensed intellectual property relating to the use of PARP inhibitor drugs for treating vascular disease to CYCLE Pharmaceuticals.
› Verified 7 days ago
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
Abortion opponents have found a new way to restrict access to abortion - by using the authority states have over the new health insurance exchanges, which will be up and running in a year. At least 21 states have legislation in place or in the works that will stop health insurance companies from paying for abortions for women.
On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA's current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.
Baxter International Inc. and Takeda Pharmaceutical Company Limited today announced that the parties have completed a Development, License and Technology Transfer Agreement. Under the terms of the agreement, Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market.
Forward Pharma A/S, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares.
Cambridge Enterprise has exclusively licensed intellectual property relating to the use of PARP inhibitor drugs for treating vascular disease to CYCLE Pharmaceuticals.
› Verified 7 days ago
| Entity Name | Pinnacle Health Medical Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932143427 PECOS PAC ID: 7618960493 Enrollment ID: O20040407000180 |
News Archive
Abortion opponents have found a new way to restrict access to abortion - by using the authority states have over the new health insurance exchanges, which will be up and running in a year. At least 21 states have legislation in place or in the works that will stop health insurance companies from paying for abortions for women.
On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA's current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.
Baxter International Inc. and Takeda Pharmaceutical Company Limited today announced that the parties have completed a Development, License and Technology Transfer Agreement. Under the terms of the agreement, Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market.
Forward Pharma A/S, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares.
Cambridge Enterprise has exclusively licensed intellectual property relating to the use of PARP inhibitor drugs for treating vascular disease to CYCLE Pharmaceuticals.
› Verified 7 days ago
| Entity Name | Gslpg, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366006702 PECOS PAC ID: 7810226875 Enrollment ID: O20190917001763 |
News Archive
Abortion opponents have found a new way to restrict access to abortion - by using the authority states have over the new health insurance exchanges, which will be up and running in a year. At least 21 states have legislation in place or in the works that will stop health insurance companies from paying for abortions for women.
On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA's current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.
Baxter International Inc. and Takeda Pharmaceutical Company Limited today announced that the parties have completed a Development, License and Technology Transfer Agreement. Under the terms of the agreement, Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market.
Forward Pharma A/S, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares.
Cambridge Enterprise has exclusively licensed intellectual property relating to the use of PARP inhibitor drugs for treating vascular disease to CYCLE Pharmaceuticals.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Frank Charles Damico, MD 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109-4839 Ph: (717) 724-0720 | Mr Frank Charles Damico, MD 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109-4839 Ph: (717) 724-0720 |
News Archive
Abortion opponents have found a new way to restrict access to abortion - by using the authority states have over the new health insurance exchanges, which will be up and running in a year. At least 21 states have legislation in place or in the works that will stop health insurance companies from paying for abortions for women.
On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA's current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.
Baxter International Inc. and Takeda Pharmaceutical Company Limited today announced that the parties have completed a Development, License and Technology Transfer Agreement. Under the terms of the agreement, Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market.
Forward Pharma A/S, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares.
Cambridge Enterprise has exclusively licensed intellectual property relating to the use of PARP inhibitor drugs for treating vascular disease to CYCLE Pharmaceuticals.
› Verified 7 days ago
Mr. Peter Joseph Tucker, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109 Phone: 717-724-0720 Fax: 717-724-0730 | |
Mr. Emerson Leroy Knight Jr., MD Urology Medicare: Medicare Enrolled Practice Location: 304 N Paxtang Ave, Harrisburg, PA 17111 Phone: 717-982-8420 Fax: 717-564-6212 | |
Jose N Prudencio Jr., M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109 Phone: 717-724-0720 Fax: 717-724-0730 | |
Mr. George Bernard Boline Jr., MD Urology Medicare: Accepting Medicare Assignments Practice Location: 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109 Phone: 717-724-0720 Fax: 717-724-0730 | |
Lewis E Harpster, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109 Phone: 717-724-0720 Fax: 717-724-0730 | |
Vanessa Elliott, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109 Phone: 717-724-0720 Fax: 717-724-0730 |